[Devics neuromyelitis optica. Disease or variants of multiple sclerosis?].
Neuromyelitis optica (NMO, or Devic's syndrome) is a rare syndrome characterized by the combination of acute or subacute optic neuritis and transverse myelitis. This strict confinement of lesions together with immunologic parameters such as frequent absence of oligoclonal banding despite increased signs of CSF inflammation suggest that NMO is distinct from multiple sclerosis (MS). Magnetic resonance imaging (MRI) data support NMO and MS as separate entities due to lesion distribution and signal characteristics. This is further supported by epidemiological and genetic evidence associating HLA-DRB1*1501 with disseminated "western" MS in contrast to NMO associated with DRB1*802, DPB1 501, and DPA1 202, the "Asian" type. Most findings suggest a heterogeneous pathogenesis of NMO and, in spite of the distinct localization, rather unspecific immune reactions seem to be involved. As to the frequent relapses of NMO, therapeutic options besides prednisolone are difficult to assess and favor long-term immune suppression or modulation.
Haase
C G
CG
Klinik und Poliklinik für Neurologie, Universität Essen. clausgert.haase.ch@bayer-ag.de
D001208:Asia / Q000453:epidemiology; D020278:Demyelinating Autoimmune Diseases, CNS / Q000175:diagnosis; D003937:Diagnosis, Differential; D005060:Europe / Q000453:epidemiology; D020022:Genetic Predisposition to Disease; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000175:diagnosis*; D009471:Neuromyelitis Optica / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000628:therapy; D010956:Plasmapheresis
D005938:Glucocorticoids; D007166:Immunosuppressive Agents